Phreesia (NYSE:PHR) PT Raised to $31.00

Phreesia (NYSE:PHR) had its target price lifted by equities research analysts at Truist Financial from $29.00 to $31.00 in a research note issued on Friday, Benzinga reports. The firm currently has a “buy” rating on the stock. Truist Financial’s target price indicates a potential upside of 25.66% from the stock’s previous close.

Several other equities analysts also recently weighed in on PHR. Canaccord Genuity Group reissued a “buy” rating and set a $34.00 target price on shares of Phreesia in a research report on Thursday. Robert W. Baird boosted their price objective on shares of Phreesia from $31.00 to $34.00 and gave the company an “outperform” rating in a research report on Friday. JMP Securities reissued a “market outperform” rating and issued a $30.00 target price on shares of Phreesia in a research note on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $29.00 price target on shares of Phreesia in a research note on Thursday. Finally, Stephens reissued an “overweight” rating and issued a $28.00 price objective on shares of Phreesia in a research report on Friday, May 31st. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $30.92.

Phreesia Trading Down 4.0 %

NYSE PHR traded down $1.02 during trading hours on Friday, hitting $24.67. 64,033 shares of the company were exchanged, compared to its average volume of 466,952. Phreesia has a 52 week low of $12.05 and a 52 week high of $29.16. The company has a quick ratio of 1.76, a current ratio of 1.76 and a debt-to-equity ratio of 0.03. The stock has a 50-day moving average price of $23.33 and a 200 day moving average price of $22.82. The stock has a market cap of $1.42 billion, a PE ratio of -11.68 and a beta of 0.93.

Insider Activity

In related news, Director Mark Douglas Smith sold 7,000 shares of the stock in a transaction that occurred on Thursday, July 18th. The stock was sold at an average price of $25.00, for a total value of $175,000.00. Following the transaction, the director now owns 30,653 shares of the company’s stock, valued at $766,325. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other news, COO Evan Roberts sold 1,669 shares of the business’s stock in a transaction on Tuesday, July 16th. The stock was sold at an average price of $23.74, for a total value of $39,622.06. Following the completion of the transaction, the chief operating officer now directly owns 753,234 shares of the company’s stock, valued at approximately $17,881,775.16. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. Also, Director Mark Douglas Smith sold 7,000 shares of the stock in a transaction dated Thursday, July 18th. The shares were sold at an average price of $25.00, for a total transaction of $175,000.00. Following the sale, the director now directly owns 30,653 shares of the company’s stock, valued at $766,325. The disclosure for this sale can be found here. Over the last quarter, insiders sold 29,337 shares of company stock valued at $736,750. Corporate insiders own 5.80% of the company’s stock.

Hedge Funds Weigh In On Phreesia

Several institutional investors and hedge funds have recently bought and sold shares of PHR. nVerses Capital LLC boosted its position in shares of Phreesia by 76.5% in the 2nd quarter. nVerses Capital LLC now owns 3,000 shares of the company’s stock worth $64,000 after purchasing an additional 1,300 shares in the last quarter. Russell Investments Group Ltd. increased its position in Phreesia by 5,462.3% during the 4th quarter. Russell Investments Group Ltd. now owns 3,838 shares of the company’s stock valued at $89,000 after buying an additional 3,769 shares in the last quarter. EntryPoint Capital LLC purchased a new stake in Phreesia in the first quarter valued at about $169,000. Quadrature Capital Ltd acquired a new stake in Phreesia in the first quarter worth about $202,000. Finally, Lombard Odier Asset Management USA Corp acquired a new stake in Phreesia in the second quarter worth about $202,000. 92.10% of the stock is owned by hedge funds and other institutional investors.

Phreesia Company Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.